DNA methylation markers for breast cancer prognosis: Unmasking the immune component

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 962-964

  Dedeurwaerder, Sarah ^a   Fuks, François ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Breast cancer; DNA methylome; Epigenomics; Lymphocyte infiltration; Tumor microenvironment

Indexed keywords

ARTICLE; BREAST CANCER; CANCER IMMUNOLOGY; CANCER PROGNOSIS; CANCER THERAPY; CD3D GENE; CD3G GENE; CD6 GENE; CORRELATION ANALYSIS; DISEASE COURSE; DNA METHYLATION; DNA METHYLATION PROFILING; GENE; GENE EXPRESSION; HUMAN; ICOS GENE; IMMUNOCOMPETENT CELL; ITGAL GENE; LAX1 GENE; LCK GENE; MARKER GENE; PREDICTION; PRIORITY JOURNAL; SIT1 GENE; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; UBASH3A GENE;

EID: 84886944203     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19996     Document Type: Article

References (10)

1. Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 2007; 7:791-9; PMID:17851544; http://dx.doi.org/10.1038/nrc2212.
2. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360:790-800; PMID:19228622; http://dx.doi.org/10.1056/ NEJMra0801289.
3. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31:27-36; PMID:19752007; http://dx.doi.org/10.1093/carcin/bgp220.
4. Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, Shen R, et al. Genome-wide DNA meth-ylation profiling using Infinium® assay. Epigenomics 2009; 1:177-200; PMID:22122642; http://dx.doi.org/10.2217/epi.09.14.
5. Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F. Evaluation of the Infinium Methylation 450K technology. Epigenomics 2011; 3:771-84; PMID:22126295; http://dx.doi.org/10.2217/epi.11.105.
6. Dedeurwaerder S, Desmedt C, Calonne E, Singhal SK, Haibe-Kains B, Defrance M, et al. DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol Med 2011; 3:726-41; PMID:21910250; http://dx.doi.org/10.1002/ emmm.201100801.
7. Dedeurwaerder S, Fumagalli D, Fuks F. Unravelling the epigenomic dimension of breast cancers. Curr Opin Oncol 2011; 23:559-65; PMID:21946247; http://dx.doi.org/10.1097/CCO.0b013e32834bd481.
8. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadju-vant chemotherapy in breast cancer. J Clin Oncol 2010; 28:105-13; PMID:19917869; http://dx.doi.org/10.1200/JCO.2009.23.7370.
9. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14:518-27; PMID:18438415; http://dx.doi.org/10.1038/nm1764.
10. Wilson CB, Rowell E, Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 2009; 9:91-105; PMID:19151746; http://dx.doi.org/10.1038/nri2487.